Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Powers Forward With First-Line Tecentriq In Advanced NSCLC

Executive Summary

The actual data on the clinically meaningful effect on PFS of the triple combination of Tecentriq, Avastin and chemotherapy on previously untreated advanced NSCLC patients in the IMpower150 study have now been presented at a scientific meeting, and suggest that Roche could be a significant competitor in the large NSCLC market in the not too distant future.


Related Content

ASH In Review: Roche Refreshes Hematology Portfolio With Robust New Drugs
Sanofi Sees Cemiplimab As Path To Relevance In Immuno-Oncology
AZ Rides PACIFIC Wave To Be First In Early-Stage NSCLC


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts